Tasigna

Tasigna is a brand name of nilotinib, approved by the FDA in the following formulation(s):

TASIGNA (nilotinib hydrochloride monohydrate - capsule; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: October 29, 2007
  
  Strength(s): EQ 200MG BASE ^[RLD]


• 
  Manufacturer: NOVARTIS
  
  Approval date: June 17, 2010
  
  Strength(s): EQ 150MG BASE
  

Has a generic version of Tasigna been approved?

No. There is currently no therapeutically equivalent version of Tasigna available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tasigna. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Inhibitors of tyrosine kinases
  Patent 7,169,791
  Issued: January 30, 2007
  Inventor(s): Breitenstein; Werner & Furet; Pascal & Jacob; Sandra & Manley; Paul William
  Assignee(s): Novartis AG
  The invention relates to compounds of formula wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.
  
  Patent expiration dates:
  
  
  • July 4, 2023
    
    ✓ 
    Patent use: A METHOD FOR THE TREATMENT OF LEUKEMIAS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 29, 2012 - NEW CHEMICAL ENTITY
  
  
  • June 17, 2013 - TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.
  
  
  • June 17, 2014 - TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.
  
  
  • October 29, 2014 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Tasigna Consumer Information (Drugs.com)
• Tasigna Consumer Information (Wolters Kluwer)
• Tasigna Consumer Information (Cerner Multum)
• Tasigna Advanced Consumer Information (Micromedex)
• Tasigna AHFS DI Monographs (ASHP)
• Nilotinib Consumer Information (Wolters Kluwer)
• Nilotinib Consumer Information (Cerner Multum)
• Nilotinib Advanced Consumer Information (Micromedex)
• Nilotinib AHFS DI Monographs (ASHP)